LXRX
Lexicon Pharmaceuticals, Inc. [LXRX] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
LXRX Stock Summary
Top 10 Correlated ETFs
LXRX
Top 10 Correlated Stocks
LXRX
In the News
LXRX Financial details
Company Rating
-
Market Cap
485.09M
Income
-174.58M
Revenue
1.21M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
285
Optionable
No
Shortable
Yes
Earnings
30 Apr 2024
P/E
-2.31
Forward P/E
-
PEG
-0.84
P/S
682.65
P/B
-0.21
P/C
-
P/FCF
-2.69
Quick Ratio
6.78
Current Ratio
6.92
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0.79
EPS next Y
-
EPS next Q
-
EPS this Y
29.03%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
NAN%
Revenue last 5Y
-67.3%
Revenue Q/Q
333.33%
EPS Q/Q
-4.76%
-
-
-
-
SMA20
-6.41%
SMA50
-2.67%
SMA100
-54.38%
Inst Own
-
Inst Trans
-
ROA
-57%
ROE
10%
ROC
-0.64%
Gross Margin
97%
Oper. Margin
-29245%
Profit Margin
-29575%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.92-3.79
52W High
-
52W Low
-
RSI
43.55
Rel Volume
0.67
Avg Volume
4.78M
Volume
3.18M
Perf Week
2.16%
Perf Month
-23.65%
Perf Quarter
-58.72%
Perf Half Y
-62.83%
-
-
-
-
Beta
1.275
-
-
Volatility
0.03%, 0.08%
Prev Close
-2.2%
Price
0.71
Change
-4.18%
Company Profile
- Volume Average 4.78M
- Market Capitalization 485.09M
- Employee 285
- CEO Mr. Lonnel Coats
- Headquarters The Woodlands,TX,US
- IPO Date 2000-04-07
-
Website
https://www.lexpharma.com 
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain. The company has strategic collaboration and license agreements with Bristol-Myers Squibb Company, and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in The Woodlands, Texas.
